We are live on ! Find out more
ODT

Odonate Therapeutics, Inc. Common Stock

Delisted

ODT was delisted on the 14th of January, 2022.

45 hedge funds and large institutions have $471M invested in Odonate Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

73% more funds holding

Funds holding: 2645 (+19)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

13% less capital invested

Capital invested by funds: $541M → $471M (-$69.4M)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
45
Holders Change
+19
Holders Change %
+73.08%
% of All Funds
1.03%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
26
Increased
7
Reduced
9
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FMA
51
FNY Managed Accounts
New York
-$2K -100 Closed
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
+$165 +7 New

ODT Hedge Fund Activity: Q1 2018 in Review

45 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q1 2018, worth a combined $471M — down 13% from $541M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ODT positions and 7 closed out — a net gain of 19 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $6.7M. The largest seller was Millennium Management, exiting entirely with an estimated $2.28M sold.

  • 45 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q1 2018, up from 26 in Q4 2017.
  • Funds reported $471M of Odonate Therapeutics, Inc. Common Stock stock for Q1 2018, down 13% quarter-over-quarter.
  • 26 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q1 2018 and 7 closed out, a net change of +19 holders.
  • The largest Odonate Therapeutics, Inc. Common Stock buyer in Q1 2018 was BlackRock, an estimated $6.7M added.
  • The largest Odonate Therapeutics, Inc. Common Stock seller in Q1 2018 was Millennium Management, an estimated $2.28M sold.

Based on aggregated 13F filings for Q1 2018.